Initial Dosing of Romiplostim for Immune Thrombocytopenia

Dosing Protocol for ITP

The American Society of Hematology recommends an initial dose of romiplostim of 1 mcg/kg administered subcutaneously once weekly, with subsequent dose adjustments based on platelet response, to achieve a platelet count ≥50 × 10^9/L 1, 2
Romiplostim, a thrombopoietin receptor agonist, stimulates platelet production by activating the thrombopoietin receptor, and the dose can be adjusted weekly by increments of 1 mcg/kg until the patient achieves a platelet count ≥50 × 10^9/L 1
The maximum dose of romiplostim should not exceed 10 mcg/kg per week, and dose adjustments should be made based on platelet response, with the goal of maintaining platelet counts between 50-200 × 10^9/L 1, 2

Platelet counts should be monitored weekly until a stable platelet count (≥50 × 10^9/L for at least 4 weeks without dose adjustment) is achieved, and if platelet count exceeds 200 × 10^9/L, romiplostim should be temporarily withheld until platelet count falls below 200 × 10^9/L, then resumed at a reduced dose 1
If platelet count remains below 50 × 10^9/L after 4 weeks at the maximum dose of 10 mcg/kg, romiplostim should be discontinued as ineffective 1

Bone marrow evaluations have revealed transiently increased blast counts in some patients with myelodysplastic syndromes, raising concerns about potential progression to acute myeloid leukemia 3, 4
Worsening thrombocytopenia may occur upon discontinuation of romiplostim, and liver function test abnormalities have been reported with TPO receptor agonists 1, 5

Romiplostim is considered a maintenance therapy due to its mechanism of action; most patients return to lower platelet counts upon cessation of treatment 6

For patients with stable responses for at least 6 months, tapering can be considered 7
Recommended tapering for romiplostim: reduce by 1 mcg/kg/week every 2 weeks until reaching 1 mcg/kg/week 7
Then administer 1 mcg/kg every other week for two to three administrations, followed by once every three weeks before discontinuation 7
Monitor closely for rebound thrombocytopenia upon discontinuation 6

The American Society of Hematology recommends monitoring complete blood counts with platelet counts weekly until a stable dose is achieved during the dose adjustment phase, and reducing monitoring to monthly once platelet counts are stable 8
The American Society of Hematology suggests exercising caution in patients with preexisting thrombotic risk factors, as thrombotic events occurred in 6.5% of patients in long-term studies 8
Bone marrow reticulin formation can occur but is typically mild, asymptomatic, and reversible upon treatment interruption, according to the American Journal of Hematology 8

Platelet response typically occurs within 1-4 weeks in patients with counts <30 × 10^9/L, with overall response rates of 88% in non-splenectomized patients and 79% in splenectomized patients, as reported by the American Society of Hematology 9, 10
Worsening thrombocytopenia may occur upon abrupt cessation of romiplostim, which is a recognized serious adverse event, emphasizing the need for gradual tapering and monitoring 9, 10
Common adverse events (≥20% of patients) include headache, fatigue, epistaxis, arthralgia, and contusion, with similar incidence to placebo groups, as noted by the American College of Clinical Pharmacology 9, 10

Approximately 30% of patients may achieve sustained remission lasting ≥6 months after discontinuation, according to Blood Reviews 11

Hepatic adverse events should be monitored in patients receiving romiplostim, although liver toxicity is more commonly associated with eltrombopag. 12

In patients whose baseline platelet count is low (e.g., <30 × 10⁹/L), a therapeutic platelet response typically emerges within 1–4 weeks of initiating romiplostim. 12
Overall response rates to romiplostim are high: approximately 88 % of patients without prior splenectomy achieve a satisfactory platelet response, compared with about 79 % of splenectomized patients. 12
When an adequate dose is administered, more than 80 % of patients demonstrate a measurable increase in platelet count by day 15 of therapy. 12